Sai Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sai Liu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ali Etemadi
Division of Nephrology, Department of Medicine, Stanford University, Stanford, California
2 shared publications - Tara I. Chang
Division of Nephrology, Department of Medicine, Stanford University, Stanford, California
2 shared publications - Gomathy Parvathinathan
Stanford University School of Medicine
1 shared publication - Jun Young Lee
Department of Nephrology, Yonsei University Wonju College of Medicine, Wonju, South Korea
1 shared publication - Margaret R. Stedman
Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, USA
1 shared publication - Maria E. Montez- Rath
Division of Nephrology, Department of Medicine, Stanford University, Stanford, California
1 shared publication
Latest Publications
- Open Access
- 2 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (11) , e048230
Balancing Days at Home and Major Adverse Limb Events After Surgical Versus Endovascular Lower‐Extremity Revascularization in Chronic Kidney Disease
Background: The risk–benefit trade‐offs after lower‐extremity revascularization among older patients with chronic kidney disease remain unclear. We compared how surgical versus endovascular lower‐extremity revascularization associates with clinical outcomes that may be valued differently by patients. Methods: We selected adults aged ≥66 years with chronic kidney disease who underwent lower‐extremity revascularization from January 1, 2008, to December 31, 2017, with ≥12 months Medicare Parts A and B before the procedure. The primary outcome was days at home at 30, 180, and 365 days after revascularization. The secondary outcome was major adverse limb events (ie, lower‐extremity revascularization or major amputation). We report outcomes as the difference in survived days at home and days lost due to major adverse limb events by restricted mean time lost. Results: Among 87 446 patients, 15.3% underwent surgical and 84.7% underwent endovascular revascularization. Surgical revascularization was associated with fewer days at home at 30 days (difference, −8.4 [95% CI, −8.6 to −8.2]), 180 days (difference, −21.2 [95% CI, −22.1 to −20.4]) and 365 days (difference, −31.9 [95% CI, −33.5 to −30.6]) compared with endovascular. Surgical revascularization was associated with fewer days lost to major adverse limb events at 180 days (difference, −6.9 [95% CI, −7.6 to −5.8]) and at 365 days (difference, −17.3 [95% CI, −19.3 to −14.7]). Conclusions: In this study of older patients with chronic kidney disease, surgical lower‐extremity revascularization was associated with fewer survived days at home, but also with fewer days lost to major adverse limb events compared with an endovascular approach. Considering different risk–benefit profiles when planning for lower‐extremity revascularization is essential to facilitate shared decision making.
- 2 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (11) , e048230
Open AccessBalancing Days at Home and Major Adverse Limb Events After Surgical Versus Endovascular Lower‐Extremity Revascularization in Chronic Kidney Disease
Background: The risk–benefit trade‐offs after lower‐extremity revascularization among older patients with chronic kidney disease remain unclear. We compared how surgical versus endovascular lower‐extremity revascularization associates with clinical outcomes that may be valued differently by patients. Methods: We selected adults aged ≥66 years with chronic kidney disease who underwent lower‐extremity revascularization from January 1, 2008, to December 31, 2017, with ≥12 months Medicare Parts A and B before the procedure. The primary outcome was days at home at 30, 180, and 365 days after revascularization. The secondary outcome was major adverse limb events (ie, lower‐extremity revascularization or major amputation). We report outcomes as the difference in survived days at home and days lost due to major adverse limb events by restricted mean time lost. Results: Among 87 446 patients, 15.3% underwent surgical and 84.7% underwent endovascular revascularization. Surgical revascularization was associated with fewer days at home at 30 days (difference, −8.4 [95% CI, −8.6 to −8.2]), 180 days (difference, −21.2 [95% CI, −22.1 to −20.4]) and 365 days (difference, −31.9 [95% CI, −33.5 to −30.6]) compared with endovascular. Surgical revascularization was associated with fewer days lost to major adverse limb events at 180 days (difference, −6.9 [95% CI, −7.6 to −5.8]) and at 365 days (difference, −17.3 [95% CI, −19.3 to −14.7]). Conclusions: In this study of older patients with chronic kidney disease, surgical lower‐extremity revascularization was associated with fewer survived days at home, but also with fewer days lost to major adverse limb events compared with an endovascular approach. Considering different risk–benefit profiles when planning for lower‐extremity revascularization is essential to facilitate shared decision making.
- 20 May 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (11) , 2506-2516
Nondialyzable versus Dialyzable β-Blockers in Hemodialysis
Key Points: Many major adverse cardiovascular events happen within the first 6 months after hemodialysis initiation. Using nondialyzable β -blockers at hemodialysis initiation was associated with fewer cardiovascular events than dialyzable β -blockers. Background: How β -blocker dialyzability affects cardiovascular outcomes in patients receiving hemodialysis remains unclear. Previous observational studies show conflicting results, and conducting clinical trials in this population has proven challenging. This uncertainty has contributed to substantial variation in β -blocker prescribing patterns across regions and clinicians. Methods: Using data from the United States Renal Data System, we identified patients receiving β -blockers on the day of starting hemodialysis and classified them into nondialyzable and dialyzable exposure groups. Geographical variations in nondialyzable and dialyzable β -blocker prescription rates across neighboring regions in each state were leveraged as an instrumental variable. The treatment effect of nondialyzable versus dialyzable β -blockers on major adverse cardiovascular events (MACE) at 6 months, 1 year, and 3 years was evaluated using instrumental variable g -estimation methods for survival outcomes. MACE comprised myocardial infarction, stroke, and all-cause mortality. Results: The cohort of 40,313 participants from 41 US states experienced 25,720 MACE over the 3-year follow-up period (median years [interquartile range], 1.4 [0.4–3.0]), with more than 42% occurring during the first 6 months after hemodialysis initiation. The instrumental variable met all statistical assumptions. Nondialyzable β -blockers were associated with significantly lower risk of MACE at all three follow-up time points compared with dialyzable β -blockers (hazard ratios [95% confidence intervals], 0.82 [0.74 to 0.90], 0.85 [0.79 to 0.92], and 0.90 [0.85 to 0.96], respectively). Similar patterns were observed for each separate component of MACE. Conclusions: The use of nondialyzable β -blockers compared with dialyzable β -blockers was associated with a lower risk of MACE during all time points, including the early, high-risk period in the 6 months following hemodialysis initiation.
- 20 May 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (11) , 2506-2516
Nondialyzable versus Dialyzable β-Blockers in Hemodialysis
Key Points: Many major adverse cardiovascular events happen within the first 6 months after hemodialysis initiation. Using nondialyzable β -blockers at hemodialysis initiation was associated with fewer cardiovascular events than dialyzable β -blockers. Background: How β -blocker dialyzability affects cardiovascular outcomes in patients receiving hemodialysis remains unclear. Previous observational studies show conflicting results, and conducting clinical trials in this population has proven challenging. This uncertainty has contributed to substantial variation in β -blocker prescribing patterns across regions and clinicians. Methods: Using data from the United States Renal Data System, we identified patients receiving β -blockers on the day of starting hemodialysis and classified them into nondialyzable and dialyzable exposure groups. Geographical variations in nondialyzable and dialyzable β -blocker prescription rates across neighboring regions in each state were leveraged as an instrumental variable. The treatment effect of nondialyzable versus dialyzable β -blockers on major adverse cardiovascular events (MACE) at 6 months, 1 year, and 3 years was evaluated using instrumental variable g -estimation methods for survival outcomes. MACE comprised myocardial infarction, stroke, and all-cause mortality. Results: The cohort of 40,313 participants from 41 US states experienced 25,720 MACE over the 3-year follow-up period (median years [interquartile range], 1.4 [0.4–3.0]), with more than 42% occurring during the first 6 months after hemodialysis initiation. The instrumental variable met all statistical assumptions. Nondialyzable β -blockers were associated with significantly lower risk of MACE at all three follow-up time points compared with dialyzable β -blockers (hazard ratios [95% confidence intervals], 0.82 [0.74 to 0.90], 0.85 [0.79 to 0.92], and 0.90 [0.85 to 0.96], respectively). Similar patterns were observed for each separate component of MACE. Conclusions: The use of nondialyzable β -blockers compared with dialyzable β -blockers was associated with a lower risk of MACE during all time points, including the early, high-risk period in the 6 months following hemodialysis initiation.